The work, by MDI biological laboratory scientist Aric Rogers, could lead to new class of anti-aging therapies.
MDI Biological Laboratory (ME, USA) scientist Aric Rogers has received a grant of US$455,000 over two years from the National Institute on Aging, one of the institutes of the National Institutes of Health, for research on the cellular mechanisms governing longevity. The grant will allow Rogers to delve more deeply into his discovery that nonsense-medicated decay (NMD), a regulatory mechanism that governs a wide array of genetic functions, also plays a critical role in extending longevity under conditions of dietary restriction (DR).
“We have found that the restriction and redirection of NMD has a major influence on the extension of lifespan under conditions of DR,” Rogers explained. “The takeaway is that the NMD pathway is a requirement for the increase in longevity that occurs with DR; if it doesn’t work properly, lifespan extension is forfeited.”
DR, which typically involves a dramatic reduction in calories without malnutrition, has been known for many years to extend lifespan and delay or reduce the risk of many age-related diseases in a wide range of species, from single-celled yeasts to primates.
The role of DR in prolonging healthy lifespan has set scientists on a quest to identify drug candidates called “DR mimetics” that mimic the effects of DR on longevity. The use of such drugs would allow patients to experience the health- and lifespan-enhancing effects of DR without the difficulty of adhering to a diet that drastically cuts calories.
“The fact that NMD is already a target for therapeutic manipulation is good news,” Rogers continued. “Since drug candidates vary in their targets, effectiveness and the speed with which they move through the development process, an expanded pipeline increases the likelihood that life-extending therapies will soon become available.”
In the classical model, NMD functions as a quality control mechanism by removing aberrant gene products that could result in the production of deleterious proteins. However, mutations can cause NMD to inappropriately target certain proteins, resulting in cancers and genetic disorders such as cystic fibrosis and hemophilia.
Rogers’ data suggest a revised model in which NMD functions like a control panel that helps an organism adapt to environmental stressors such as food scarcity by changing gene activity levels. Thus, drugs that target NMD could be used to trigger the adaptive responses normally associated with DR, bypassing the need for extreme dieting.
“The identification of NMD’s role in longevity opens the door to the development of new therapies to prolong lifespan,” said Kevin Strange, MDI Biological Laboratory president. “This grant from the National Institutes of Health will help expedite Dr. Rogers’ important research on elucidating the genetic pathways of aging.”
Source: MDI Biological Laboratory press release